
TVGN Stock Forecast & Price Target
TVGN Analyst Ratings
Bulls say
Tevogen Bio Holdings is currently making significant strides in advancing their ExacTcell platform across various fields, including virology, oncology, and neurology. This is supported by their recent investment in Tevogen.AI and their indication of evaluating further life sciences-related transactions, indicating a desire to build an integrated and scalable healthcare enterprise. However, the recent decline in their share price has potentially impacted their capital formation and balance sheet flexibility, leading us to increase our dilution assumptions and push out our commercialization timeline to 2029. This in turn brings potential risks including clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks.
Bears say
Tevogen Bio Holdings is facing significant challenges that could hinder its future success and growth. The announcement of a reverse stock split has caused negative sentiment among retail investors and could result in reduced liquidity and a shrinking shareholder base. While the potential acquisition of a contract research organization could improve the company's operational control and earnings visibility, it is not guaranteed and no assurance of completion. Overall, the company's dilution risk, delayed commercialization timeline, and potential difficulties in advancing its ExacTcell platform could impact its stock negatively and make it a risky investment option.
This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.
TVGN Analyst Forecast & Price Prediction
Start investing in TVGN
Order type
Buy in
Order amount
Est. shares
0 shares